A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION
Sponsor: |
F. Hoffmann-La Roche Ltd |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS1555 |
U.S. Govt. ID: |
NCT03866239 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to explore the effects, good or bad, of Cibisatamab, atezolizumab, obinutuzumab, and tocilizumab on patients with Colorectal cancer (CRC). In this study, you will first get treated with obinutuzumab (hereafter referred to as pretreatment with obinutuzumab). About 2 weeks later, you will then get treated with Cibisatamab and atezolizumab. If you have a bad reaction to Cibisatamab and atezolizumab, you may also get treated with tocilizumab. About 50 people will take part in this study.
This study is closed
Investigator
Gulam Manji, MD, PhD
Are you 18 years of age or older? |
Yes |
No |
Do you have histologically confirmed adenocarcinoma originating from the colon or rectum? |
Yes |
No |
Have you experienced disease progression during or within 3 months? |
Yes |
No |